339 related articles for article (PubMed ID: 34478505)
41. Richter transformation of chronic lymphocytic leukemia in the era of novel agents.
Wang Y; Ding W
Clin Adv Hematol Oncol; 2020 Jun; 18(6):348-357. PubMed ID: 32649656
[TBL] [Abstract][Full Text] [Related]
42. Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia.
Davids MS; Hallek M; Wierda W; Roberts AW; Stilgenbauer S; Jones JA; Gerecitano JF; Kim SY; Potluri J; Busman T; Best A; Verdugo ME; Cerri E; Desai M; Hillmen P; Seymour JF
Clin Cancer Res; 2018 Sep; 24(18):4371-4379. PubMed ID: 29895707
[No Abstract] [Full Text] [Related]
43. The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism.
Anderson MA; Deng J; Seymour JF; Tam C; Kim SY; Fein J; Yu L; Brown JR; Westerman D; Si EG; Majewski IJ; Segal D; Heitner Enschede SL; Huang DC; Davids MS; Letai A; Roberts AW
Blood; 2016 Jun; 127(25):3215-24. PubMed ID: 27069256
[TBL] [Abstract][Full Text] [Related]
44. Venetoclax for the treatment of patients with chronic lymphocytic leukemia.
Crombie J; Davids MS
Future Oncol; 2017 Jun; 13(14):1223-1232. PubMed ID: 28492339
[TBL] [Abstract][Full Text] [Related]
45. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.
Stilgenbauer S; Eichhorst B; Schetelig J; Coutre S; Seymour JF; Munir T; Puvvada SD; Wendtner CM; Roberts AW; Jurczak W; Mulligan SP; Böttcher S; Mobasher M; Zhu M; Desai M; Chyla B; Verdugo M; Enschede SH; Cerri E; Humerickhouse R; Gordon G; Hallek M; Wierda WG
Lancet Oncol; 2016 Jun; 17(6):768-778. PubMed ID: 27178240
[TBL] [Abstract][Full Text] [Related]
46. How I manage CLL with venetoclax-based treatments.
Wierda WG; Tambaro FP
Blood; 2020 Apr; 135(17):1421-1427. PubMed ID: 32076705
[TBL] [Abstract][Full Text] [Related]
47. Pneumocystis jirovecii pneumonia and institutional prophylaxis practices in CLL patients treated with BTK inhibitors.
Ryan CE; Cheng MP; Issa NC; Brown JR; Davids MS
Blood Adv; 2020 Apr; 4(7):1458-1463. PubMed ID: 32282880
[TBL] [Abstract][Full Text] [Related]
48. Current Therapeutic Sequencing in Chronic Lymphocytic Leukemia.
Mouhssine S; Maher N; Kogila S; Cerchione C; Martinelli G; Gaidano G
Hematol Rep; 2024 Apr; 16(2):270-282. PubMed ID: 38804280
[TBL] [Abstract][Full Text] [Related]
49. Outcomes for Patients With Chronic Lymphocytic Leukemia (CLL) Previously Treated With Both a Covalent BTK and BCL2 Inhibitor in the United States: A Real-World Database Study.
Mato AR; Hess LM; Chen Y; Abada PB; Konig H; Pagel JM; Walgren RA
Clin Lymphoma Myeloma Leuk; 2023 Jan; 23(1):57-67. PubMed ID: 36335022
[TBL] [Abstract][Full Text] [Related]
50. Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
Izutsu K; Yamamoto K; Kato K; Ishikawa T; Fukuhara N; Terui Y; Choi I; Humphrey K; Kim SY; Okubo S; Ogawa N; Nishimura Y; Salem AH; Maruyama D
Int J Hematol; 2021 Mar; 113(3):370-380. PubMed ID: 33094474
[TBL] [Abstract][Full Text] [Related]
51. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease.
Roberts AW; Seymour JF; Brown JR; Wierda WG; Kipps TJ; Khaw SL; Carney DA; He SZ; Huang DC; Xiong H; Cui Y; Busman TA; McKeegan EM; Krivoshik AP; Enschede SH; Humerickhouse R
J Clin Oncol; 2012 Feb; 30(5):488-96. PubMed ID: 22184378
[TBL] [Abstract][Full Text] [Related]
52. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment.
Hallek M
Am J Hematol; 2019 Nov; 94(11):1266-1287. PubMed ID: 31364186
[TBL] [Abstract][Full Text] [Related]
53. Improved Survival of Patients With Chronic Lymphocytic Leukemia Between 1998-2022, Including the Era of Target Therapies With BCL2 and BTK Inhibitors.
Tadmor T; Melamed G; Alapi H; Gazit S; Patalon T; Rokach L
Anticancer Res; 2024 May; 44(5):2109-2115. PubMed ID: 38677726
[TBL] [Abstract][Full Text] [Related]
54. Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia.
Cervantes-Gomez F; Lamothe B; Woyach JA; Wierda WG; Keating MJ; Balakrishnan K; Gandhi V
Clin Cancer Res; 2015 Aug; 21(16):3705-15. PubMed ID: 25829398
[TBL] [Abstract][Full Text] [Related]
55. Treatment algorithm for Japanese patients with chronic lymphocytic leukemia in the era of novel targeted therapies.
Kojima K; Burger JA
J Clin Exp Hematop; 2020 Dec; 60(4):130-137. PubMed ID: 32404571
[TBL] [Abstract][Full Text] [Related]
56. Richter transformation in the era of novel agents.
Ding W
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):256-263. PubMed ID: 30504319
[TBL] [Abstract][Full Text] [Related]
57. Venetoclax: A Review in Relapsed/Refractory Chronic Lymphocytic Leukemia.
Scott LJ
Target Oncol; 2019 Oct; 14(5):493-504. PubMed ID: 31542870
[TBL] [Abstract][Full Text] [Related]
58. Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
Maddocks KJ; Ruppert AS; Lozanski G; Heerema NA; Zhao W; Abruzzo L; Lozanski A; Davis M; Gordon A; Smith LL; Mantel R; Jones JA; Flynn JM; Jaglowski SM; Andritsos LA; Awan F; Blum KA; Grever MR; Johnson AJ; Byrd JC; Woyach JA
JAMA Oncol; 2015 Apr; 1(1):80-7. PubMed ID: 26182309
[TBL] [Abstract][Full Text] [Related]
59. Frontline Treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Targeted Therapy vs. Chemoimmunotherapy.
Small S; Ma S
Curr Hematol Malig Rep; 2021 Aug; 16(4):325-335. PubMed ID: 34021874
[TBL] [Abstract][Full Text] [Related]
60. A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL.
Jain N; Senapati J; Thakral B; Ferrajoli A; Thompson P; Burger J; Basu S; Kadia T; Daver N; Borthakur G; Konopleva M; Pemmaraju N; Parry E; Wu CJ; Khoury J; Bueso-Ramos C; Garg N; Wang X; Lopez W; Ayala A; O'Brien S; Kantarjian H; Keating M; Allison J; Sharma P; Wierda W
Blood Adv; 2023 May; 7(10):1958-1966. PubMed ID: 36287248
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]